To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Clinical trial NCT05541822 · RECRUITING
Trial details
- NCT number
- NCT05541822
- Sponsor
- Abion Inc
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-17
- Primary completion
- 2029-02-01
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.